Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk Transcript
Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk Transcript
Monte Rosa Therapeutics: High-Stakes Drug Pipeline Balanced By A Fortress Balance Sheet
Monte Rosa Therapeutics is rated a risky Buy, with valuation hinging on the clinical success and milestone payments from its outlicensed flagship asset MRT-6160. MRT-6160, targeting autoimmune diseases, offers differentiated safety and oral convenience, with Phase 2 results as the key near-term catalyst for GLUE. GLUE maintains a robust $626 million cash position, providing a 3.5-year runway and cushioning downside risk amid high clinical trial expenses.
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.15 per share a year ago.
Monte Rosa: Initiating Coverage With A Buy On Degrader Platform Potential
Monte Rosa Therapeutics, Inc. is a leading biotech in molecular glue degraders, with a $1.45bn valuation and robust partnerships with Novartis and Roche. GLUE's pipeline shows promising Phase 1 data, especially for MRT-8102 and MRT-6160, but lacks Phase 2 proof-of-concept results to fully derisk programs. Significant cash runway ($675m) and milestone-rich deals provide operational security while awaiting pivotal clinical readouts and potential Novartis milestones.
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to earnings of $0.57 per share a year ago.
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise
A GLUE executive disposed of 8,000 shares for a transaction value of approximately $141,000 at a weighted average price of around $17.64 per share on April 14, 2026. The sale represented 1.30% of their direct common stock holdings, reducing their directly held common shares from 613,471 to 605,471.
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to earnings of $0.23 per share a year ago.
Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Monte Rosa Therapeutics (GLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug
Monte Rosa shares surge 45% after interim phase I data show that MRT-8102 drives deep NEK7 degradation and reduces sharp inflammation markers.
Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable
Monte Rosa Therapeutics (GLUE) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Monte Rosa Therapeutics (GLUE) Upgraded to Strong Buy: Here's Why
Monte Rosa Therapeutics (GLUE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.43 per share a year ago.
